Euro Diagnostica AB signs agreement with Arquer Diagnostics Ltd

Euro Diagnostica AB (Euro Diagnostica) has signed an agreement for the manufacturing and supply of Arquer Diagnostics Ltd (Arquer)’s Mcm5-ELISA test for the diagnosis of bladder cancer.

Bladder cancer is currently diagnosed by cystoscopy, which is expensive and uncomfortable for patients. Arquer has developed a high sensitivity, high specificity, ELISA-based non-invasive test, which detects the presence of minichromosome maintenance complex component 5 (Mcm5) protein in urine. MCM proteins are shed into urine by both prostate and bladder tumours and are known to be excellent biomarkers of cancer, being directly involved in cell replication. Arquer’s diagnostic test originates from work conducted by Cambridge University and Cancer Research Technology (CRT).

“It is with great pleasure we engage in this partnership with Arquer, which indeed substantiates Euro Diagnostica’s ambition to be a preferred partner, meeting the ever-growing demands within the IVD/Biotech world. As a manufacturer, Euro Diagnostica can offer tailored technical state-of-the art solutions based on experience and competence. We look forward to a mutually successful long-term business relation.” says Else Beth Trautner, CEO, Euro Diagnostica

Dr Ian Campbell, CEO, Arquer Diagnostics, commented: “This agreement is an important milestone for Arquer, as we move towards European regulatory approval and prepare for the commercial launch of the Mcm5-ELISA test later this year. With Euro Diagnostica’s experience in the manufacture of ELISA kits, we are confident that this relationship will allow us to bring the Mcm5-ELISA test to market in the most efficient, rapid, and cost effective manner possible, to benefit both patients and clinicians.”

Under the terms of the agreement, Euro Diagnostica will be the primary manufacturer of Arquers´ Mcm5-ELISA test kits.